The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.
Ivanikov I.O.
Pirogov Russian National Research Medical University;
Central Clinical Hospital of Russian Federation Presidential Administration
Grigorieva Yu.V.
Pirogov Russian National Research Medical University;
Central Clinical Hospital of Russian Federation Presidential Administration
Nikonov E.L.
Pirogov Russian National Research Medical University
Liver injury in COVID-19: clinical features and risk factors
Journal: Russian Journal of Evidence-Based Gastroenterology. 2023;12(3): 51‑62
Read: 4430 times
To cite this article:
Zharova ME, Ivanikov IO, Grigorieva YuV, Nikonov EL. Liver injury in COVID-19: clinical features and risk factors. Russian Journal of Evidence-Based Gastroenterology.
2023;12(3):51‑62. (In Russ.)
https://doi.org/10.17116/dokgastro20231203151
Elevated liver enzymes are present in 9% to 24.7% of COVID-19 patients and correlate with disease severity. The pathogenesis and risk factors for liver damage in COVID-19 patients remain incompletely understood.
To identify risk factors and characteristics of liver damage in patients with COVID-19.
We examined 200 medical records of COVID-19 patients who were admitted to the Central Clinical Hospital, Moscow from March 2020 to July 2021. Patients underwent general clinical, laboratory, and instrumental examinations.
A total of 166 patients (83%) had elevated liver enzymes, with 145 (86.8%) showing elevations below 5 ULN with the predominance of a cytolytic pattern. The use of paracetamol and amoxicillin with clavulanic acid was associated with an increased frequency of liver damage. The likelihood of liver damage in COVID-19 patients surged by 8.35-fold (95% CI: 2.49; 30.05, p=0.0006) with the use of five or more medications concurrently. Peak concentrations of AST and ALT were associated with COVID-19 severity and mortality. In three patients, autoimmune hepatitis was diagnosed 6—12 months after recovery from COVID-19.
The findings of this research highlight the complex origins of liver injury in COVID-19. Elevation of liver enzymes occurs more frequently than previously assumed and can persist even after recovery, being associated with a severe SARS-CoV-2 infection. Therefore, incorporating liver function tests into standard monitoring protocols during hospitalization and post-discharge is recommended.
Authors:
Ivanikov I.O.
Pirogov Russian National Research Medical University;
Central Clinical Hospital of Russian Federation Presidential Administration
Grigorieva Yu.V.
Pirogov Russian National Research Medical University;
Central Clinical Hospital of Russian Federation Presidential Administration
Nikonov E.L.
Pirogov Russian National Research Medical University
Received:
22.05.2023
Accepted:
23.08.2023
List of references:
Close metadata
Email Confirmation
An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.
Email Confirmation
Log in to the site using your account in one of the services
We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.